characteristics were obtained from WHO estimates or local sources, adjusted to local conditions. PSS23 direct and indirect effectiveness was extrapolated from PCV7 trials and surveillance records, adjusted to local serotype distribution. Cost of vaccine was USD 16.34. A discount rate for cost and life-years was 3%. The payer and societal perspectives were considered. RESULTS: The budget impact in a single- payer model with PCV13 was expected in place where amount to USD 1.82 million, or USD 7.9 million without indirect vaccine protection considered. From this investment, 141 971 illnesses (1071 IIDs, 12477 CAPs and 128423 OMs) and 347 deaths could be avoided. Direct medical costs, indirect vaccine protection, 58 524 illnesses (601 IIDs, 4721 CAP, 53202 OM) and 184 deaths could be avoided. The cost-effectiveness analysis produced ICER of USD 340/LYG or USD 367/QALY from the payer’s perspective. From the societal perspective, the NIP is dominant. Not considering indirect protection, the ICER would be USD 140/LYG or USD 152/QALY from a societal perspective. The ICER for the NIP in Sweden was USD 7.93 million without indirect lifetime protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered. From this investment, 7.93 million without indirect vaccine protection considered.